Actively Recruiting
Phase I Study of Oral HS-10516 for Safety and Effectiveness in Adults with VHL Syndrome Associated Tumors
Led by Jiangsu Hansoh Pharmaceutical Co., Ltd. · Updated on 2024-08-14
60
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying HS-10516, an oral HIF-2b1 inhibitor, in Chinese patients aged 18 to 80 years who have Von Hippel Lindau VHL Syndrome associated tumors, including advanced clear cell renal cell carcinoma. The study aims to find the highest safe dose of HS-10516 in the Phase Ia dose escalation part and to evaluate its safety, how the body processes the drug, and its preliminary antitumor effects in Phase Ib. This open-label Phase I study is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. Participants receive HS-10516 once daily by mouth. In Phase Ia, patients are assigned to increasing dose levels to determine the maximum tolerated or acceptable dose. Phase Ib involves expanding patient groups based on tumor types and sizes, including those with VHL-associated renal cell carcinoma with lesions 64 3 cm, those with larger renal lesions, and those with non-renal tumors related to VHL syndrome. Each phase has specific treatment goals and dosing schedules. Throughout the study, participants undergo evaluations including safety monitoring, blood tests to assess drug levels, and tumor assessments reviewed by an independent committee. The primary outcomes include identifying the maximum tolerated dose in about two months and measuring tumor response over approximately one year. Secondary outcomes track adverse events, drug concentration over time, tumor control, progression-free and overall survival, with follow-up lasting up to two years. Participants must also use contraception and agree to informed consent before joining.
CONDITIONS
Brief Title
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Research Team
K
Kan Gong, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here